Research profile dashboard

Oncology navigation profile

Active treatment — monitoring response · Preparing for screening conversations

Evidence confidence map

Heuristic coverage across research areas — not clinical certainty.

Standard-of-care landscape92
How guideline pathways, staging, and multidisciplinary review frame therapy-relevant research themes.
Biomarker and molecular testing85
Assay types, tissue context, and how markers inform research eligibility — not self-directed treatment choices.
Clinical trial ecosystem92
Phase concepts, inclusion themes, and coordinator-led screening — distinct from consumer matching claims.
Supportive care and tolerance92
Symptom burden, organ function, and quality-of-life factors that shape safe clinical conversations.

Confidence reflects how much structured context you supplied for a teaching heuristic — not the statistical strength of any study or your individual prognosis.

Biomarker profile cards

Structured markers for discussion — not diagnostic interpretation.

PD-L1 expression discussed in pathology notes
context dependent
Research navigation only — marker interpretation belongs with treating specialists and pathologists.
How does "PD-L1 expression discussed in pathology notes" affect eligibility themes in oncology research?
EGFR status pending confirmation
unclear
Research navigation only — marker interpretation belongs with treating specialists and pathologists.
How does "EGFR status pending confirmation" affect eligibility themes in oncology research?
prior liquid biopsy mentioned without full report.
context dependent
Research navigation only — marker interpretation belongs with treating specialists and pathologists.
How does "prior liquid biopsy mentioned without full repor…" affect eligibility themes in oncology research?

Therapy category landscape

Category lens: Oncology — high-level research themes for clinician discussion, not a treatment plan.
Care stage framing: Active treatment — monitoring response.
Standard-of-care landscape: How guideline pathways, staging, and multidisciplinary review frame therapy-relevant research themes.
Biomarker and molecular testing: Assay types, tissue context, and how markers inform research eligibility — not self-directed treatment choices.
Clinical trial ecosystem: Phase concepts, inclusion themes, and coordinator-led screening — distinct from consumer matching claims.
Supportive care and tolerance: Symptom burden, organ function, and quality-of-life factors that shape safe clinical conversations.
Research interest noted: Immunotherapy trial concepts, biomarker-stratified studies, and supportive care research on symptom burden..
Use this landscape to prepare questions about mechanisms, evidence maturity, and logistics — not to self-select therapies.

Clinical trial readiness checklist

Preparation themes for coordinator conversations — not eligibility determination.

Diagnosis and staging documentation gathered
Needs review
Collect official clinical summaries for your physician — this navigator does not verify diagnosis.
Biomarker and pathology records organized
Ready to discuss
Original reports with dates and assay methods support accurate research eligibility discussions.
Treating clinician aligned on trial exploration
Needs review
Enrollment conversations should include your primary treating specialist, not this educational tool alone.
Travel, caregiver, and scheduling constraints documented
Needs review
Feasibility affects real screening — note constraints before coordinator calls.
Informed consent and registry literacy reviewed
Needs review
Understand that trials have protocols, monitoring, and withdrawal rights — coordinators explain specifics.
Safety labs and medication list ready for screening
Needs review
Organ function and concomitant medications are reviewed by licensed clinicians during real screening.

Evidence gaps

Areas where additional context or clinician input would strengthen research navigation.

Personal evidence map vs. public literature
Without clinician synthesis, research papers may not map to your full clinical picture.
Ask your specialist which review sources (guidelines, tumor boards, registries) apply to your case.
Symptom timeline and functional impact
Trials and supportive research often stratify by symptom burden and performance status.
Document onset, triggers, and functional changes since your last clinical visit.

Physician discussion brief

Exportable conversation scaffold — your clinician validates all clinical conclusions.

Physician discussion brief (educational navigation — not medical advice): I used N1 Therapeutics to organize research context for our conversation. My selected category is Oncology. Care stage: Active treatment — monitoring response. Trial interest: Preparing for screening conversations. Biomarker themes I am tracking: PD-L1 expression discussed in pathology notes; EGFR status pending confirmation; prior liquid biopsy mentioned without full report. Symptoms I want to contextualize: Fatigue with activity, intermittent cough, appetite changes over several weeks — seeking structured questions for oncology follow-up. Care goal for this discussion: Understand which research areas apply to my situation and prepare a concise brief for my next specialist visit. Research areas I want to explore: Immunotherapy trial concepts, biomarker-stratified studies, and supportive care research on symptom burden. I would like help understanding which evidence sources apply to me, what trial screening might realistically involve, and which risks require in-person evaluation.

Questions to ask your care team

Which oncology research areas are most relevant given my current care stage (active treatment — monitoring response)?
What biomarker or pathology reports should I bring to our next visit, and which are still pending?
How do my documented symptoms change the interpretation of available research — without implying a diagnosis here?
Given my care goal (Understand which research areas apply to my situation and prepare a concise brief for my n…), what evidence sources should we prioritize reviewing together?
My trial interest level is "preparing for screening conversations" — what screening steps are realistic before any enrollment conversation?
What safety monitoring, organ function tests, or medication interactions should we discuss before research pathways?
Which questions are better addressed by a genetic counselor, trial coordinator, or subspecialist referral?

Care discussion plan

Open with care goals and what you hope to learn — not a request for the clinician to endorse self-directed therapy choices.
Review biomarker and symptom worksheets as conversation anchors; invite correction of any misinterpretation.
Align on how active treatment — monitoring response changes which research themes are timely.
Identify whether genetic counseling, trial coordination, or subspecialty referral is the next appropriate step.
Close with documented follow-ups: tests to obtain, questions for coordinators, and revisit timing.

Next research steps

Export or copy your physician brief and bring primary source documents to your visit.
List open questions from the care discussion plan and mark which require coordinator input.
Revisit research interest (Immunotherapy trial concepts, biomarker-stratified studies, and supportive care …) after clinician feedback.
Verify any trial names or IDs through official registries before assuming eligibility.
Update this worksheet when new pathology, imaging, or care-stage changes occur.

Safety and scope

N1 Therapeutics organizes research-relevant context for educational discussion with licensed clinicians. It does not diagnose conditions, recommend treatments, interpret labs as medical fact, or predict outcomes. All therapy and trial decisions require qualified healthcare professionals and official trial coordinators.